To view or add a comment, sign in Lilly's Triple Agonist, Retatrutide, Shines in First Phase 3 Trial Retatrutide is a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist
Unlike GLP-1 agonists such as semaglutide or tirzepatide, which work primarily through appetite suppression, AOD-9604 directly enhances fat metabolism at the cellular level through beta-3 adrenergic receptor modulation
Field trials integrating physiological, molecular, and agronomic data should evaluate trait stability, metabolite persistence, and effects on nutrient cycling and soil microbial dynamics
Until then, the proposal is not yet final law
4 weeks (1 vial): ~3 mL 1 bottle 8 weeks (23 vials): ~69 mL 1 bottle Alcohol Swabs One for the vial stopper + one for the injection site each day